MarketPulse

stem cell therapy

9 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Stem Cell Therapy Market Surges to $58.5B by 2034 on Tech, Regulation Tailwinds

Global stem cell therapy market projected to grow from $21.9B in 2025 to $58.5B by 2034 at 11% CAGR, driven by technological advances and favorable regulations.
TAKVCELSMDPYclinical trialsregenerative medicine
BenzingaBenzinga··Usa News Group

Biotech Race to Commercialize Longevity Science Heats Up as Market Eyes $29.7B Prize

Longevity biotech sector surges toward $29.7B market by 2034 as companies advance cell therapies for age-related diseases, with multiple clinical programs showing promising results.
VRTXLGVNLCTXOCGNclinical trialsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Spinal Cord Injury Market Set to Quadruple as Six Therapies Challenge Treatment Void

Spinal cord injury market projected to grow from $354M to $1.4B by 2034 as six emerging therapies target previously untreated condition.
ABBVNGENclinical trialsmarket growth
BenzingaBenzinga··Prnewswire

BrainStorm Charts Recovery Path With $2M Funding as NurOwn Advances to Pivotal ALS Trial

BrainStorm Cell Therapeutics reported $10.3M net loss for 2025 while securing $2M financing and advancing NurOwn into Phase 3b ALS study following FDA clearance.
BCLIfinancial resultsprivate placement
GlobeNewswire Inc.GlobeNewswire Inc.··Mordor Intelligence

Orthobiologics Market Set to Hit $9.5B by 2031 as Regenerative Medicine Surges

Global orthobiologics market projected to grow 43% to $9.52B by 2031, driven by rising osteoarthritis and regenerative therapy advancements.
JNJSYKMDTZBHBVS+1regenerative medicinestem cell therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Biorestorative Therapies, Inc.

BioRestorative Therapies to Showcase Regenerative Skincare Tech at Major NYC Wellness Event

BioRestorative Therapies will exhibit at Be+Well Beauty and Wellness Show in NYC (March 8-10, 2026) to advance its BioCosmeceutical platform commercialization.
BRTXclinical developmentregenerative medicine
BenzingaBenzinga··Prnewswire

Brainstorm Cell Therapeutics Completes $2M February Fundraising Round

Brainstorm Cell Therapeutics raised $2M in February through private placement at $0.60/share. Funds support general operations, regulatory work, and Phase 3b trial preparations for ALS therapy NurOwn.
BCLIprivate placementcapital raise
BenzingaBenzinga··Prnewswire

Brainstorm Cell Raises $1M Through Private Placement Above Current Valuation

Brainstorm Cell raised $1M via private placement at $0.60/share, above market price. Funds support Phase 3b ALS therapy trials and regulatory efforts.
BCLIprivate placementstem cell therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BioRestorative Closes $5M Equity Offering to Fund Stem Cell Pipeline

BioRestorative raised $5M through equity offering to advance stem cell therapies, including BRTX-100 for spine disease and metabolic disorder research.
BRTXclinical trialsregenerative medicine